The study will take seven years and will focus on the effects of shorter-term treatment of uncomplicated candidemia, the most common invasive fungal disease in children.
“This study will build a foundation for improved guidelines that allow us to treat children more rapidly, reduce the medicine they need and get them back to thriving quickly,” William Steinbach, MD, the study’s co-principal investigator and pediatrician-in-chief at Arkansas Children’s, said in an Aug. 29 news release. “The results also will inform future trials in adults and allow us to change guidelines for care of all patients with these diseases.”
The study will be one of the first to research different durations of treatment for invasive fungal disease.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
